PPAR α/γ Agonist in Management of Diabetic Dyslipidemia: A Review
Journal Title: International Journal of Clinical Pharmacology & Toxicology(IJCPT) - Year 2015, Vol 4, Issue 1
Abstract
Cardiovascular diseases are major contributors of mortality and morbidity in patients with type 2 diabetes mellitus (T2DM), while dyslipidemia and hyperglycemia are key modifiable risk factors to prevent coronary artery disease (CAD). Although healthy diet, regular physical activity and maintaining a normal body weight are advised, patients generally require single or multiple drugs to treat T2DM. Moreover, patients with T2DM are prone to atherogenic diabetic dyslipidemia (ADD), which is characterized by elevated triglyceride, small dense LDL particles and low High-density lipoprotein (HDL) cholesterol. Even though low-density lipoprotein cholesterol (LDL) remains the primary target of therapy, non-high density lipoprotein (non-HDL) cholesterol is as an important parameter to be considered in clinical practice. Unfortunately, high-dose statin therapy is not advised for long term, as it can increase risk of new onset T2DM. On the other hand, glitazars are newer molecules having dual peroxisome proliferator-activated receptors (PPAR) α/γ agonistic action that can improve lipid profile with improvement of insulin sensitivity. In conclusion, the overall safety of saroglitazar is acceptable due to minimal side effects, but improvement of β cell function, effect on insulin sensitivity by analysis of insulin resistance index by using the homeostatic model assessment (HOMAIR) and long term cardiovascular benefits like atherosclerotic plaque stabilization or regression need to be confirmed.
Authors and Affiliations
Radhika A. Vaishnav
Keywords
Related Articles
- EP ID EP201713
- DOI 10.19070/2167- 910X-1500026
- Views 90
- Downloads 0
Liquid-Liquid Extraction vs Solid Phase Extraction in Biological Fluids and Drugs
Liquid-Liquid Extraction vs Solid Phase Extraction in Biological Fluids and Drugs
Steady State Plasma Levels of Bupropion After Administration of 3x150 Mg Extended Release Reference Tablets and Switching to 1x450 Mg Extended Release 450ER Tablets
In order to provide patients who take 450 mg/day bupropion hydrochloride for the treatment of severe depressive disorder with a safe and convenient alternative to currently existing dose regimens, a high-dose bupropion E...
Anticancer Agents: A Review of Relevant Information on Important Herbal Drugs
Cancer has almost created havoc amongst the human society as the number of mortalities is increasing day-by-day and year after year. Numerous studies have been done to find out the cure for cancer but to no avail. Herbal...
Decomposition of Concentration-Time Profiles after Oral Administration of Different Ethanol Doses in Humans
A new physiologically-motivated structural model capable of evaluating ethanol behavior within the whole-body blood metabolism was developed. This model was estimated on the basis of a reanalysis of the mean blood ethano...
Assessment of Fatigue and Its Associated Factors in Breast Cancer Patients Under Treatment
Fatigue is a common distressing problem in most beast cancer patients. It may be caused by the disease, the complications of the disease and its treatments. This study aimed to assess fatigue and associated factors in br...